Seagen Financial News

29.10 / 12:57
UPS CEO Pfizer Research Seagen reports medicines Pfizer’s strong quarter bolsters CEO’s comeback efforts
Subscribe to enjoy similar stories. Pfizer punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results. The pharmaceutical company raised its revenue outlook for the year to between $61 billion to $64 billion, up from $59.5 billion to $62.5 billion previously.
29.10 / 16:51
Waves Pfizer pandemic Trade Seagen Vaccines Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year
13.08 / 17:30
CEO Pfizer Seagen Vaccines Pharmaceuticals Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world
14.04 / 08:45
markets UPS Pfizer Research Healthcare Seagen Two brothers, a big biotech bet and an $8 billion payout
A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by brothers Felix and Julian Baker, had in 2003 invested in Seagen, a developer of next-generation cancer treatments.
14.12 / 15:31
Target Moderna Pfizer BioNTech vaccine Seagen Vaccines Pfizer shares sink on declining demand for COVID vaccines, treatment
Pfizer on Wednesday forecast 2024 sales that were as much as $5 billion below Wall Street expectations due mostly to declining demand for COVID vaccines and treatment, driving shares down seven per cent in premarket trading.
07.12 / 16:33
Target Art Merck Seagen ImmunoGen show reports Although it took a while, targeted cancer drugs lived up to the hype
how to do it in a manner that could make them a staple of cancer care. That’s reflected in pharma companies’ sudden deep commitment to the space. In addition to AbbVie’s acquisition, other deals this year include Pfizer’s proposed $43 billion buyout of Seagen, Merck & Co’s $4 billion tie-up with Daiichi Sankyo, and a series of smaller investments from Bristol-Myers Squibb and Eli Lilly & Company.
06.09 / 17:33
COST UPS BLOCK Action Pfizer Amgen Seagen Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
A weak party can get a much stronger opponent to back down, game theory explains, by signaling it is willing to take extreme actions and bear steep costs. But that sort of brinkmanship arguably works only if you don’t have to actually fight—and lose—repeatedly. Federal Trade Commission Chair Lina Khan has been open about her willingness to take on hard cases and lose.
01.08 / 15:35
Manufacturing Assurant Pfizer Seagen track Pfizer Q2 Results: Profit tumbles 77% to $2.3 billion; co trims 2023 revenue outlook
Pfizer reported a steep drop in profits Tuesday on much lower Covid-related revenues as it curtailed its full-year sales outlook, in part due to tornado damage to a key manufacturing facility. Profits in the second quarter were $2.3 billion, down 77% as revenues fell 54% to $12.7 billion. Quarterly revenues for Pfizer's Covid-19 vaccine and Paxlovid therapeutic were $1.6 billion, far below the $16.9 billion in the year-ago period.
30.06 / 11:15
UPS FIVE JPMorgan Compilation Chase Seagen Time Goldman Sachs loses top M&A ranking for first time in five years
Goldman Sachs Group has lost its ranking as the world’s top mergers and acquisitions adviser for the first time in five years.
27.02 / 16:49
CEO Pfizer Seagen Stocks making the biggest moves premarket: Best Buy, Seagen, Union Pacific and more
Check out the companies making headlines before the bell.
10.08 / 02:25
UPS Merck Biogen Seagen Why healthcare is currently the market’s best sector
Michael Brush is a columnist for MarketWatch. At the time of publication, he had no positions in any stocks mentioned here. Brush has suggested Seagen, Merck, BioMarin, Biogen, Bristol-Myers Squibb and Zimmer Biomet in his newsletter, Brush Up on Stocks

what you should know about Seagen

What is Seagen and why is it important?

Seagen is a significant category that interests a wide audience. On our site, we regularly publish news related to this subject.

Where can I find the latest updates on Seagen?

All new posts about Seagen can be found in the special selection. We publish information regularly.

How can I verify the accuracy of information on Seagen?

We consult with professionals to ensure that the information about Seagen is reliable and helpful for our readers.